AI in Drug Discovery Market to Reach $25.0 Billion by 2035 at 12.6% CAGR | Insilico Medicine, Optibrium, BenevolentAI

The global AI in drug discovery market, valued at USD 6.0 billion in 2025 and projected to hit USD 8.6 billion in 2026, is on course to reach USD 25.0 billion by 2035, growing at a compound annual growth rate (CAGR) of 12.6% over the forecast period 2026 to 2035. Pharmaceutical companies, biotechs, and contract research organizations are investing heavily in machine learning and generative AI platforms to compress drug development timelines and reduce attrition rates that have long plagued traditional discovery pipelines.

To explore the complete findings, request a free sample of the report at https://www.rootsanalysis.com/reports/ai-based-drug-discovery-market/request-sample.html

Market Overview
The AI in drug discovery market sits at the intersection of two urgent global pressures: the escalating burden of chronic and complex diseases, and the inadequacy of conventional pharmaceutical R&D methods to address them quickly or cost-effectively. Conditions including cancer, neurological disorders, cardiovascular diseases, and infectious diseases collectively represent some of the largest unmet medical needs in the world. Aging demographics in North America, Europe, and parts of Asia-Pacific are amplifying demand for faster, more precise therapeutic solutions, pushing pharmaceutical and biotech firms to seek alternatives to the trial-and-error methods that define traditional discovery.

AI platforms address this gap directly. By processing vast multi-omics datasets, including genomic, proteomic, and real-world clinical data, these systems enable capabilities that were not practical even five years ago: virtual screening of billions of molecular candidates, de novo drug design, predictive toxicology, and automated lead optimization. The industry has moved well past the proof-of-concept phase. Insilico Medicine advanced ISM001-055, a drug candidate developed entirely using generative AI, into Phase II clinical trials for idiopathic pulmonary fibrosis, a milestone that signals genuine commercial confidence in AI-guided development. In January 2026, Cresset raised USD 300 million from Constellation Wealth Capital and Blue Owl Capital to accelerate its AI-powered computational chemistry platform for small molecule design. Receptor AI secured a separate Series A round the same month to scale its deep learning platform for predicting protein-ligand interactions.

Strategic collaborations are also gaining pace. In December 2025, LabGenius Therapeutics entered a partnership with Sanofi to apply machine learning to antibody optimization across multiple therapeutic targets, a deal that reflects growing interest from major pharmaceutical firms in integrating AI-native workflows directly into their preclinical pipelines.

Key Growth Drivers
Escalating R&D Investment and Venture Capital Activity. The AI drug discovery sector has attracted substantial venture capital in recent years, particularly for platforms that demonstrate measurable gains in target identification, molecular interaction prediction, and lead optimization. This investment momentum is not slowing. Multi-hundred-million-dollar funding rounds in early 2026 alone confirm that institutional capital views AI-driven discovery as a durable, high-return category rather than an early-stage experiment.

Expanding Biomedical Datasets. The growing volume of structured biomedical data from genomics repositories, proteomics platforms, and real-world evidence sources gives machine learning models an increasingly strong foundation for pattern recognition. AI platforms can identify novel targets and surface drug repurposing opportunities at a scale that human researchers cannot match, driving adoption among biotech firms that prioritize data-driven efficiency.

Shift to Generative AI and Autonomous Lab Systems. Generative models such as generative adversarial networks, transformers, and reinforcement learning architectures allow companies to design novel chemical structures optimized for binding affinity, ADMET properties, and synthesizability without screening pre-existing compound libraries. Separately, autonomous AI-driven laboratory systems now run continuous design-build-test-learn cycles around the clock, integrating directly with generative AI workflows to accelerate hit identification. Merck KGaA's AIDDISON platform, which combines deep learning with computer-aided drug design, illustrates how established pharmaceutical companies are embedding these capabilities into their core R&D infrastructure.

Favorable Regulatory Support in Leading Markets. The U.S. Food and Drug Administration has introduced frameworks that acknowledge and support the use of AI and machine learning technologies in drug development. These policy signals reduce regulatory uncertainty for companies building AI-first discovery pipelines and encourage further platform development and commercial adoption.

Clinical Validation Building Commercial Confidence. As AI-derived drug candidates move from preclinical stages into human trials, the industry's confidence in these platforms grows. Each Phase II or Phase III entry for an AI-designed molecule strengthens the business case for broader adoption, creating a reinforcing cycle between clinical progress and investment.

Market Segmentation
The AI in drug discovery market segments by drug discovery step, AI technology type, therapeutic area, end user, and geography. Among drug discovery steps, lead optimization holds the largest share, accounting for approximately 50% of the overall market. This reflects the substantial resources pharmaceutical companies commit to chemical synthesis modifications, comprehensive ADMET profiling, and efficacy-potency refinement, stages where AI platforms deliver the clearest productivity gains through predictive modeling and high-throughput screening.

Machine learning is the dominant AI technology type, holding a 40% market share. Oncological disorders capture the largest therapeutic area share at approximately 20%, a position that reflects both the scientific complexity of cancer biology and the sheer volume of clinical and genomic data available for training AI models. Pharma and biotech companies are the leading end users, expected to hold roughly 75% of revenue share by 2035, given their financial resources, strategic urgency to accelerate drug pipelines, and established computational infrastructure.

To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/ai-based-drug-discovery-market/request-quote.html

Regional Insights
North America holds more than 50% of the global AI in drug discovery market share, a position driven by a combination of factors that other regions have not yet replicated at scale. Substantial R&D investment from both the private sector and federal agencies, a mature healthcare IT infrastructure, and FDA regulatory frameworks that actively accommodate AI and machine learning applications all reinforce the region's leadership. The United States in particular concentrates the largest share of AI-focused pharmaceutical startups and the deepest pools of venture capital funding for the sector.

Asia-Pacific is the fastest-growing region and is expected to maintain a higher CAGR than any other geography through 2035. China's "Made in China 2025" national strategy and India's National Strategy for Artificial Intelligence are channeling significant public investment into AI infrastructure and healthcare data systems. The region also benefits from large, diverse patient datasets that give AI training models the variety needed for robust performance across different disease populations.

Competitive Landscape
The AI in drug discovery market features a mix of specialized startups, established computational chemistry firms, and increasingly, large pharmaceutical companies building proprietary AI capabilities. Key players profiled in the Roots Analysis report include BenevolentAI, Collaborations Pharmaceuticals, CytoReason, Deargen, Deep Genomics, Genialis, Healx, Insilico Medicine, Iktos, Optibrium, and XtalPi, among others.

The market is not yet consolidating around a small number of dominant platforms. Competition centers on differentiation through proprietary datasets, the specificity of AI models for particular disease areas, and the ability to demonstrate measurable reductions in discovery timelines or costs. As industry expert James Halle, Chief Commercial Officer of Optibrium, noted in the report, platforms that can quantify their value, for instance by documenting a 70 to 80% reduction in synthetic and experimental effort, are pulling ahead of peers that cannot yet make a comparable business case. Strategic partnerships between AI platform providers and major pharmaceutical companies are becoming a primary route to both commercial validation and market expansion.

Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/ai-based-drug-discovery-market.html

Contact Details
Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.